Kopran

Kopran Diluted EPS

The Diluted Earnings per Share of Kopran (KOPRAN.NS) as of Oct 30, 2026 is 7.98 INR. In the previous year, Diluted Earnings per Share was 10.54 INR — a change of -24.24% (lower).

Diluted EPS

7.98INR

YoY

-24.24%

Last updated:

Diluted Earnings per Share of Kopran is 2025 7.98 INR. Diluted Earnings per Share of Kopran was 2024 10.54 INR. It decreases by -24.24% lower compared to the previous year.

The Kopran Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2018
4.73 INR
Jan 1, 2019
5.56 INR
Jan 1, 2020
4.86 INR
Jan 1, 2021
14.24 INR
Jan 1, 2022
12.65 INR
Jan 1, 2023
5.64 INR
Jan 1, 2024
10.54 INR
Jan 1, 2025
7.98 INR
The Kopran Diluted EPS history
YEARDiluted EPSYoY
7.98INR-24.24%
10.54INR+86.92%
5.64INR-55.44%
12.65INR-11.16%
14.24INR+193.22%
4.86INR-12.57%
5.56INR+17.36%
4.73INR+2.63%
4.61INR+86.72%
2.47INR-126.10%
-9.46INR-313.99%
4.42INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kopran Stock analysis

What does Kopran do? Kopran Ltd. generates revenue through the manufacturing and sale of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company produces penicillin-based finished oral dosage forms such as anti-infective, amoxycillin, ampicillin, cloxacillin, and amoxy clauv, as well as non-penicillin-based formulations including macrolides, anti-hypertensive, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management, and gastroenterology products. Additionally, Kopran supplies APIs like anti-hypertensive, macrolides, neuromodulator, urological, anti-infective/anti-acne, sterile carbapenems, and sterile cephalosporins. These products are sold to healthcare providers, distributors, and pharmaceutical companies seeking reliable sources of finished dosage forms and APIs for their own manufacturing processes. The company's product portfolio targets multiple therapeutic segments including anti-infective, cardiovascular, and gastrointestinal treatments. Its formulations cater to both penicillin and non-penicillin-based medical needs, while APIs support a broad range of pharmaceutical applications. Kopran's manufacturing focus on finished dosage forms and APIs enables it to serve the pharmaceutical industry's demand for essential drug components without direct consumer sales. Kopran Ltd. primarily serves pharmaceutical manufacturers and healthcare distributors who require high-quality active ingredients and finished drug products. The firm's production of capsules, injectables, and tablets ensures its offerings meet diverse market needs. By specializing in both formulation and API manufacturing, Kopran positions itself as a key supplier within the pharmaceutical supply chain, providing critical components for various medical treatments. Kopran is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kopran stock

Diluted Earnings per Share of Kopran is 7.98 INR in 2025.

Diluted Earnings per Share of Kopran changed from 10.54 INR to 7.98 INR, representing a -24.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Kopran since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Kopran

All Key Metrics — Kopran